

## **Supplementary Material**

**Part 1.** Details of the literature search in each individual database

**Part 2.** Details of the direct and indirect estimates of the meta-analysis.

### **Title**

Effect of Needle Gauge Size on Pain during Intravitreal Anti-VEGF Injection: A Systematic Review and Network Meta-Analysis

### **Authors**

Emilie T. S. Butler, MS <sup>1</sup>; Jakob Bjerager, MD <sup>1</sup>; Nathalie S. Eriksen, MD <sup>2</sup>;  
Javad N. Hajari, MD PhD <sup>1,3</sup>; Miklos Schneider, MD PhD <sup>1,4</sup>; Carsten Faber, MD PhD <sup>1,3</sup>;  
Yousif Subhi, MD PhD <sup>1,2,5</sup>

### **Affiliations**

1. Department of Ophthalmology, Rigshospitalet, Glostrup, Denmark.
2. Department of Ophthalmology, Zealand University Hospital, Roskilde, Denmark.
3. Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
4. Department of Ophthalmology, Semmelweis University, Budapest, Hungary
5. Department of Clinical Research, University of Southern Denmark, Odense, Denmark.

### **Corresponding author**

Yousif Subhi, MD PhD, FEBO, assoc. professor. Department of Clinical Research, University of Southern Denmark, J.B. Winsløvs Vej 19.3, 5000 Odense C, Denmark.

### **E-mail**

ysubhi@gmail.com

**Part 1.** Details of the literature search in each individual database.

**PubMed:**

History and Search Details Download Delete

Search	Actions	Details	Query	Results	Time
#1	...	▼	<p>Search: ("intravitral"[All Fields] OR "intravitreal"[All Fields] OR "intravitreally"[All Fields] OR "intravitreous"[All Fields] OR "intravitreously"[All Fields]) AND ("pegaptanib"[Supplementary Concept] OR "pegaptanib"[All Fields] OR ("bevacizumab"[MeSH Terms] OR "bevacizumab"[All Fields] OR "bevacizumab s"[All Fields]) OR ("aflibercept"[Supplementary Concept] OR "aflibercept"[All Fields]) OR ("ranibizumab"[MeSH Terms] OR "ranibizumab"[All Fields]) OR ("brolucizumab"[Supplementary Concept] OR "brolucizumab"[All Fields]) OR ("kh902 fusion protein"[Supplementary Concept] OR "kh902 fusion protein"[All Fields] OR "conbercept"[All Fields]) OR ("faricimab"[Supplementary Concept] OR "faricimab"[All Fields])) AND ("pain"[MeSH Terms] OR "pain"[All Fields]) Sort by: Most Recent</p> <p>("intravitral"[All Fields] OR "intravitreal"[All Fields] OR "intravitreally"[All Fields] OR "intravitreous"[All Fields] OR "intravitreously"[All Fields]) AND ("pegaptanib"[Supplementary Concept] OR "pegaptanib"[All Fields] OR ("bevacizumab"[MeSH Terms] OR "bevacizumab"[All Fields] OR "bevacizumab s"[All Fields]) OR ("aflibercept"[Supplementary Concept] OR "aflibercept"[All Fields]) OR ("ranibizumab"[MeSH Terms] OR "ranibizumab"[All Fields]) OR ("brolucizumab"[Supplementary Concept] OR "brolucizumab"[All Fields]) OR ("kh902 fusion protein"[Supplementary Concept] OR "kh902 fusion protein"[All Fields] OR "conbercept"[All Fields]) OR ("faricimab"[Supplementary Concept] OR "faricimab"[All Fields])) AND ("pain"[MeSH Terms] OR "pain"[All Fields])</p>	177	12:39:19

Showing 1 to 1 of 1 entries

**EMBASE:**

Embase <1974 to 2023 October 13>

- 1 intravitreal.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword heading word, floating subheading word, candidate term word] 39625
- 2 intravitreal drug administration/ 6634
- 3 pegaptanib.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword heading word, floating subheading word, candidate term word] 2593
- 4 pegaptanib/ 2519

5 bevacizumab.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword heading word, floating subheading word, candidate term word] 77140

6 bevacizumab/ 74758

7 aflibercept.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword heading word, floating subheading word, candidate term word] 9495

8 aflibercept/ 9163

9 ranibizumab.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword heading word, floating subheading word, candidate term word] 13081

10 ranibizumab/ 12699

11 brolocizumab.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword heading word, floating subheading word, candidate term word] 620

12 brolocizumab/ 605

13 conbercept.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword heading word, floating subheading word, candidate term word] 657

14 conbercept/ 589

15 faricimab.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword heading word, floating subheading word, candidate term word] 311

16 faricimab/ 301

17 pain.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword heading word, floating subheading word, candidate term word] 1598283

18 pain/ 366016

19 1 or 2 39625

20 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 88223

21 17 or 18 1598283

22 19 and 20 and 21 708

Search History  
(22searches found)

# ▲ Searches

Results

1	intravitreal.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword heading word, floating subheading word, candidate term word]	39625
2	intravitreal drug administration/	6634
3	pegaptanib.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword heading word, floating subheading word, candidate term word]	2593
4	pegaptanib/	2519
5	bevacizumab.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword heading word, floating subheading word, candidate term word]	77140
6	bevacizumab/	74758
7	aflibercept.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword heading word, floating subheading word, candidate term word]	9495
8	aflibercept/	9163
9	ranibizumab.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword heading word, floating subheading word, candidate term word]	13081
10	ranibizumab/	12699
11	brolocizumab.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword heading word, floating subheading word, candidate term word]	620
12	brolocizumab/	605

13	conbercept.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword heading word, floating subheading word, candidate term word]	657
14	conbercept/	589
15	faricimab.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword heading word, floating subheading word, candidate term word]	311
16	faricimab/	301
17	pain.mp. [mp=title, abstract, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword heading word, floating subheading word, candidate term word]	1598283
18	pain/	366016
19	1 or 2	39625
20	3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16	88223
21	17 or 18	1598283
22	19 and 20 and 21	708

**Cochrane Central:**

Search Name:

Date Run:15/10/2023 06:02:18

Comment:

ID	Search	Hits
#1	intravitreal	4556
#2	bevacizumab OR ranibizumab OR aflibercept OR conbercept OR brolocizumab OR faricimab OR pegaptanib	10398
#3	pain	242674
#4	#1 AND #2 AND #3	129

Web of Science Core Collection, BIOSIS Previews, Current Contents Connect, Data Citation Index, Derwent Innovations Index, KCI-Korean Journal Database, Preprint Citation Index, ProQuest™ Dissertations & Theses Citation Index, and SciELO Citation Index:

**796 results from Web of Science Core Collection, BIOSIS Previews, Current Contents Connect, Data Citation Index, Derwent Innovations Index, KCI-Korean Journal Database, Preprint Citation Index, ProQuest™ Dissertations & Theses Citation Index, SciELO Citation Index:**

Analyze Results

Citation Report

 Create

Q (((((((TS=(bevacizumab)) OR TS=(aflibercept)) OR TS=(ranibizumab)) OR TS=(brolucizumab)) OR TS=...

×

More options ▾

[Search Help](#)

Query Preview

((((((((TS=(bevacizumab)) OR TS=(aflibercept)) OR TS=(ranibizumab)) OR TS=(brolucizumab)) OR TS=(pegaptanib)) OR TS=(faricimab)) OR TS=(conbercept)) AND TS=(pain) AND TS=(pain)

+ Add date range

× Clear

Search

**Part 2.** Details of the direct and indirect estimates of the meta-analysis.

ID	Comparison	Active	Control	d	LCI 95%	HCI 95%
Direct estimates						
1	32G-30G	32G	30G	0,00	-0,30	0,30
2	33G-30G	33G	30G	-0,18	-0,40	0,04
3	26G-30G	26G	30G	4,35	3,53	5,16
4	27G-30G	27G	30G	1,23	-0,20	2,66
5	29G-30G	29G	30G	1,37	1,03	1,71
6	34G-30G	34G	30G	-0,99	-1,34	-0,64
7	27G-26G	27G	26G	-0,09	-0,73	0,55
8	29G-26G	29G	26G	-2,62	-3,27	-1,97
9	29G-27G	29G	27G	-2,56	-3,14	-1,98
Indirect estimates (source IDs)						
10	Indirect 32G vs 26G (1, 3)	32G	26G	-4,35	-5,21	-3,48
11	Indirect 33G vs 26G (2, 3)	33G	26G	-4,53	-5,37	-3,68
12	Indirect 29G vs 26G (9, 7)	29G	26G	-2,65	-3,51	-1,79
13	Indirect 30G vs 26G (4, 7)	30G	26G	-1,32	-2,89	0,25
14	Indirect 30G vs 26G (5, 8)	30G	26G	-3,99	-4,72	-3,26
15	Indirect 27G vs 26G (9, 8)	27G	26G	-0,06	-0,93	0,81
16	Indirect 27G vs 26G (4, 3)	27G	26G	-3,11	-4,76	-1,47
17	Indirect 29G vs 26G (5, 3)	29G	26G	-2,97	-3,85	-2,09
18	Indirect 34G vs 26G (6, 3)	34G	26G	-5,33	-6,22	-4,45
Result estimates (source IDs)						
	32G (10)	32G	26G	-4,35	-5,21	-3,48
	30G (3, 13, 14)	30G	26G	-3,85	-5,28	-2,41
	33G (11)	33G	26G	-4,53	-5,37	-3,68
	27G (7, 15, 16)	27G	26G	-0,35	-1,86	1,16
	29G (8, 12, 17)	29G	26G	-2,72	-3,16	-2,27
	34G (18)	34G	26G	-5,33	-6,22	-4,45